Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Mark Mullikin Appointed Vedanta Biosciences CFO

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 8, 2021

Mark Mullikin brings 25 years of experience raising and deploying capital for life sciences companies and most recently held leadership roles in finance and investor relations at publicly-traded Editas Medicine and Novartis.

“Mark’s experience overseeing the finances of a public biotech and previously as a healthcare equity analyst, provide him a unique and broad perspective of the biotech field,” said Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of Vedanta Biosciences. “We are excited to welcome Mark to the Vedanta team and look forward to his contributions.”

Mark Mullikin joins Vedanta from Editas Medicine, where he served as Vice President, Finance and Investor Relations and was involved in raising $700 million of equity capital. Prior to this role, Mr. Mullikin worked for Novartis in roles focused on financial and strategic planning in addition to health economics and pricing. Before joining Novartis, he was a healthcare equity analyst at Adage Capital Management and Piper Sandler and began his career in the finance and strategy practice at Deloitte Consulting. Mr. Mullikin earned his M.B.A. in finance from the MIT Sloan School of Management and his B.A. in economics from the University of Chicago.

“Vedanta has established a leadership position in the microbiome field pioneering defined bacterial consortia as a new class of therapeutics,” said Mark Mullikin. “I am thrilled to join at this pivotal moment of growth with key clinical trial readouts anticipated this year.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine